Aurinia Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2025
-
LUPKYNIS sales grew 25% year-over-year in 2025, driving strong revenue and net income gains, aided by a significant tax benefit and share repurchases. 2026 guidance anticipates continued double-digit growth, with competition and new guidelines shaping the outlook.
-
LUPKYNIS sales surged 27% year-over-year in Q3 2025, prompting a second upward revision of 2025 guidance. New clinical data reinforced LUPKYNIS's efficacy and safety, while Aritinercept advanced toward clinical studies in two autoimmune diseases.
-
Q2 2025 saw 22% revenue growth and a sharp rise in net income, driven by LUPKYNIS sales and operational efficiency. Full-year guidance was raised, and positive Aritinercept phase I results support further clinical expansion.
-
Aritinercept's phase I study showed strong safety and robust, lasting reductions in immunoglobulins, supporting once-monthly dosing. The drug demonstrated superior potency and binding affinity versus competitors, and further studies in autoimmune diseases are planned for later this year.
-
Q1 2025 saw 24% revenue growth and a return to profitability, driven by Lupkynis sales and operational efficiency. Guidance for 2025 is reaffirmed, with continued focus on Lupkynis growth, patent defense, and upcoming AUR-200 phase I data.
Fiscal Year 2024
-
Q4 and full year 2024 saw strong revenue and Lupkynis sales growth, with improved profitability and cash flow following strategic restructuring. 2025 guidance projects continued growth, while AUR-200 development advances with phase I data expected in Q2 2025.
-
Q3 2024 saw record revenue and net income, driven by strong LUPKYNIS growth and operational efficiency. The company announced a major restructuring to focus on high-return areas, expects over $40 million in annualized savings, and reaffirmed 2024 revenue guidance.
-
Revenue and cash flow targets remain on track, with global expansion and label growth supporting the main product. Pipeline asset AUR-200 advances in early clinical studies, with a focus on B-cell-mediated diseases and strategic market selection.
-
Q2 2024 saw 38% revenue growth year-over-year, positive free cash flow, and strong patient uptake for LUPKYNIS. Guidance was narrowed to $210–$220 million, with continued commercial and pipeline progress, including AUR200 entering clinical trials.
-
LUPKYNIS continues to drive strong revenue growth, with 2024 guidance of $200–$220 million and cash flow positivity expected in Q2. Market expansion is supported by improved diagnosis, patient support, and robust clinical data, while pipeline assets and global partnerships offer future growth potential.